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Abstract: Importance Ataxia with oculomotor apraxia type 1 (AOA1) is an autosomal recessive cerebellar
ataxia due to mutations in the aprataxin gene (APTX) that is characterized by early-onset cerebellar
ataxia, oculomotor apraxia, axonal motor neuropathy, and eventual decrease of albumin serum levels.
Objectives To improve the clinical, biomarker, and molecular delineation of AOA1 and provide genotype-
phenotype correlations. Design, Setting, and Participants This retrospective analysis included the clinical,
biological (especially regarding biomarkers of the disease), electrophysiologic, imaging, and molecular data
of all patients consecutively diagnosed with AOA1 in a single genetics laboratory from January 1, 2002,
through December 31, 2014. Data were analyzed from January 1, 2015, through January 31, 2016.
Main Outcomes and Measures The clinical, biological, and molecular spectrum of AOA1 and genotype-
phenotype correlations. Results The diagnosis of AOA1 was confirmed in 80 patients (46 men [58%] and
34 women [42%]; mean [SD] age at onset, 7.7 [7.4] years) from 51 families, including 57 new (with 8 new
mutations) and 23 previously described patients. Elevated levels of ￿-fetoprotein (AFP) were found in 33
patients (41%); hypoalbuminemia, in 50 (63%). Median AFP level was higher in patients with AOA1
(6.0 ng/mL; range, 1.1-17.0 ng/mL) than in patients without ataxia (3.4 ng/mL; range, 0.8-17.2 ng/mL;
P < .01). Decreased albumin levels (￿ = -0.532) and elevated AFP levels (￿ = 0.637) were correlated with
disease duration. The p.Trp279* mutation, initially reported as restricted to the Portuguese founder
haplotype, was discovered in 53 patients with AOA1 (66%) with broad white racial origins. Oculomotor
apraxia was found in 49 patients (61%); polyneuropathy, in 74 (93%); and cerebellar atrophy, in 78 (98%).
Oculomotor apraxia correlated with the severity of ataxia and mutation type, being more frequent with
deletion or truncating mutations (83%) than with presence of at least 1 missense variant (17%; P <
.01). Mean (SD) age at onset was higher for patients with at least 1 missense mutation (17.7 [11.4] vs
5.2 [2.6] years; P < .001). Conclusions and Relevance The AFP level, slightly elevated in a substantial
fraction of patients, may constitute a new biomarker for AOA1. Oculomotor apraxia may be an optional
finding in AOA1 and correlates with more severe disease. The p.Trp279* mutation is the most frequent
APTX mutation in the white population. APTX missense mutations may be associated with a milder
phenotype.
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IMPORTANCE Ataxia with oculomotor apraxia type 1 (AOA1) is an autosomal recessive
cerebellar ataxia due tomutations in the aprataxin gene (APTX) that is characterized by
early-onset cerebellar ataxia, oculomotor apraxia, axonal motor neuropathy, and eventual
decrease of albumin serum levels.
OBJECTIVES To improve the clinical, biomarker, andmolecular delineation of AOA1 and
provide genotype-phenotype correlations.
DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis included the clinical,
biological (especially regarding biomarkers of the disease), electrophysiologic, imaging,
andmolecular data of all patients consecutively diagnosed with AOA1 in a single genetics
laboratory from January 1, 2002, through December 31, 2014. Data were analyzed from
January 1, 2015, through January 31, 2016.
MAIN OUTCOMES ANDMEASURES The clinical, biological, andmolecular spectrum of AOA1
and genotype-phenotype correlations.
RESULTS The diagnosis of AOA1 was confirmed in 80 patients (46men [58%] and 34 women
[42%]; mean [SD] age at onset, 7.7 [7.4] years) from 51 families, including 57 new (with 8 new
mutations) and 23 previously described patients. Elevated levels of α-fetoprotein (AFP) were
found in 33 patients (41%); hypoalbuminemia, in 50 (63%). Median AFP level was higher in
patients with AOA1 (6.0 ng/mL; range, 1.1-17.0 ng/mL) than in patients without ataxia
(3.4 ng/mL; range, 0.8-17.2 ng/mL; P < .01). Decreased albumin levels (ρ = −0.532) and
elevated AFP levels (ρ = 0.637) were correlated with disease duration. The p.Trp279*
mutation, initially reported as restricted to the Portuguese founder haplotype, was
discovered in 53 patients with AOA1 (66%) with broad white racial origins. Oculomotor
apraxia was found in 49 patients (61%); polyneuropathy, in 74 (93%); and cerebellar atrophy,
in 78 (98%). Oculomotor apraxia correlated with the severity of ataxia andmutation type,
beingmore frequent with deletion or truncating mutations (83%) than with presence of at
least 1 missense variant (17%; P < .01). Mean (SD) age at onset was higher for patients with at
least 1 missensemutation (17.7 [11.4] vs 5.2 [2.6] years; P < .001).
CONCLUSIONS AND RELEVANCE The AFP level, slightly elevated in a substantial fraction of
patients, may constitute a new biomarker for AOA1. Oculomotor apraxia may be an optional
finding in AOA1 and correlates with more severe disease. The p.Trp279* mutation is themost
frequent APTXmutation in the white population. APTXmissensemutations may be
associated with a milder phenotype.
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A utosomal recessive cerebellar ataxias (ARCAs) consistof a heterogeneous group of neurodegenerations dueto aprataxin mutations,1 including ataxia with oculo-
motorapraxia type 1 (AOA1).2,3Ataxiawithoculomotorapraxia
type 1 has been described as an early-onset ataxia with cer-
ebellar atrophy, oculomotor apraxia (OMA), choreodystonia,
andperipheralneuropathy.4Althoughcontroversial,OMAmay
be defined as horizontal saccades of elevated latencies com-
monly associatedwith hypometric staircase saccades, oculo-
cephalic dissociation, and/or head thrust.5,6 Ataxia with ocu-
lomotor apraxia type 1, the most frequent ARCA in Japan,7-9
hasalsobeenfound inothercountries.2,5,10-12During thecourse
of AOA1, decreased serum albumin levels and elevated se-
rum total cholesterol levels may be observed.2,5,9,10
The prevalence of OMA in AOA1 remains debatable.
Whether theα-fetoprotein (AFP) serum level is a biomarker of
AOA1 has not been elucidated, and genotype-phenotype cor-
relations need to be strengthened. In this study, we sought to
better define the clinical, biological (especially regarding bio-
markers of the disease), andmolecular spectrumofAOA1 and
to provide genotype-phenotype correlations.
Methods
Weperformed a retrospective analysis of the clinical, biologi-
cal, electrophysiologic, imaging, andmolecular data of all pa-
tients consecutivelydiagnosedwithAOA1 inourgenetics labo-
ratory at Institut de Génétique et de Biologie Moléculaire
et Cellulaire, Institut National de la Santé et de la Recherche
Medicale–U964/CentreNationalde laRechercheScientifique–
Unité Mixte de Recherche 7104/Université de Strasbourg,
Illkirch, France, from January 1, 2002, through December 31,
2014. Sequencing of theAPTX gene (OMIM606350)was per-
formed on request for cases of cerebellar ataxia with hypoal-
buminemiaand/orearly-onset cerebellar ataxiacombinedwith
peripheral neuropathy and/or cerebellar atrophy using brain
magnetic resonance imaging. The local ethics committee of
HôpitauxUniversitairesdeStrasbourg, Strasbourg,France, ap-
proved the study. All participants provided written informed
consent.
Clinical Analysis
Age at onset of the disease, duration of disease (DD), and age
at last examinationwere recorded, aswell as sex, consanguin-
ity, and geographic origin. Patients underwent neurologic ex-
amination,motor and sensory nerve conduction studies, and
brainmagnetic resonance imaging.Exhaustiveabnormal find-
ings on the clinical examination included oculomotor signs
(strabismus, saccadic pursuit, OMA, oculocephalic dissocia-
tion, and head thrust), movement disorders (chorea, dysto-
nia, parkinsonism, tremor, andmyoclonus), pyramidal signs,
areflexia, muscle wasting, ataxia, and intellectual disability.
Oculocephalicdissociationwasdefinedasdissociationbe-
tween tandem head and eye movement, with the eyes lag-
ging during head rotation. Peripheral neuropathy was de-
fined by reduced deep tendon reflexes or areflexia, distal loss
of vibration sense, and electrophysiologic evidence of nerve
conduction abnormalities. Possible cerebellar atrophy was
evaluated on sagittal and axialmagnetic resonance images by
a neuroradiologist and a neurologist.
Aspinocerebellardegenerationfunctional score (SDFS)was
used to evaluate the disability stage from 1 to 7, with higher
scores representing severe impairment.13 The SDFS corrected
for DD (SDFS:DD ratio) was used to evaluate the progression
rate of the disease. A scale of assessment and rating of ataxia
(SARA) was used to evaluate spinocerebellar degeneration.14
Biological Analysis
Wemeasured serum levels of albumin, total cholesterol, low-
density lipoprotein cholesterol, creatine kinase, andAFP. For
somepatients, severalmeasurementsofAFPandalbumin lev-
els were obtained during the course of the disease.
Mutational Analysis
WeobtainedDNAfromtotalbloodsamples frompatientsusing
standard procedures. Genetic analysis of APTX was per-
formedusing conventional Sanger sequencing. Exons 1 to 6of
APTX were amplified as previously described.2 For exon 7,
a new pair of intronic flanking primers was designed (for-
ward,5′-TATTGGTTTTCCAGAGTAGC-3′; reverse,5′-GAATAG
GTG CCA GCA GTT T-3′) and used for polymerase chain reac-
tion and amplification (10-second denaturation at 94°C, 10”
annealing at 64°C, and 10” elongation at 72°C for 35 cycles).
Polymerase chain reactionproductswerepurifiedwith a com-
mercially available kit (NucleoSpin Extract 2; Macherey-
Nagel GmbH) and sequenced from the forward and reverse
strands. Sequencingwas performedusing a Taq cycle kit (Ap-
plied Biosystems). Reaction products were run on an auto-
matedDNAsequencer (model 3100;AppliedBiosystems).Ho-
mozygous exondeletionswere readily detectedby absenceof
polymerasechainreactionamplificationproductandwereveri-
fiedwith polymerase chain reaction tests using adifferent set
of primers. In 1 case, a singleheterozygousmutationwas iden-
tified, and the copy number variation was excluded by mul-
tiplex ligation-dependentprobeamplificationanalysis (SALSA
MLPAkitP316-A1 for recessiveataxias;MRC-Holland).Thiscase
was considered to be a heterozygous carrier by chance, and a
diagnosis of AOA1 was excluded.
One patient was diagnosed using targeted exon capture
strategy coupled with multiplexing and high-throughput se-
quencing of 57 genes causing ataxia when mutated, includ-
Key Points
Questions What are the clinical, biomarker, andmolecular
delineations and genotype-phenotype correlations of ataxia with
oculomotor apraxia type 1?
Findings In this analysis of 80 patients with ataxia with
oculomotor apraxia type 1, levels of α-fetoprotein were slightly
elevated. The p.Trp279* mutation was themost frequent APTX
mutation in the white population.
Meaning Increased α-fetoprotein levels may constitute a new
biomarker of ataxia with oculomotor apraxia type 1, and
oculomotor apraxia may be correlated with more severe disease.
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ing APTX.15 When available, parents underwent sequencing
to verify segregation in trans of the mutations. For consis-
tency with most publications on APTX mutation identifica-
tion, the RefSeq gene reference NM_175073, encoding a 342–
amino acid isoform of APTX, was used for mutation report.
SerumAFP Level Measurement in Control Groups
Measurement of serum AFP levels in control individuals was
performedusing the immunoanalysisKryptorBrahmsmethod
asestablished in theLaboratoiredeBiochimieGénérale et Spé-
cialisée in theUniversityHospital of Strasbourg, France.16 The
AFP level assessmentusing thismethodwith 100healthy con-
trols provided amedian value of 3.2 ng/mLwith a 97.5th per-
centile at 7 ng/mL, which was retained as the upper limit of
normal in our study (to convert AFP levels tomicrograms per
liter,multiplyby1.0).AllhealthycontrolshadanAFPlevel from
0.5 to 15.7 ng/mL. Levels of AFPwere assessed in 102 patients
who had no cerebellar ataxia but were affected by Parkinson
disease (n = 37),atypicalparkinsonism(n = 13),Huntingtondis-
ease (n = 3), dystonia (n = 1), Alzheimer disease (n = 11), mul-
tiple sclerosis (n = 11), amyotrophic lateral sclerosis (n = 2), pe-
ripheral neuropathy (n = 16), and myopathy (n = 6).16 Levels
of AFP were assessed in 74 controls with AOA2 described
previously16 and 76patientswith sporadic late-onset cerebel-
lar ataxia (SLOCA), with a large variety of cerebellar variants
of multiple system atrophy (n = 29), dominant or recessive
ataxia (n = 9), immune-mediated causes ormalformations or
toxicorotheracquiredcauses (n = 6),orundetermined(n = 32).
Genotype-Phenotype Correlation Studies
For genotype-phenotype correlations, 2 different classifica-
tion schemeswere used. Becausemissensemutations are of-
ten hypomorphic and may cause a milder phenotype, pa-
tients with AOA1 were divided into groups with (1) at least 1
missense APTX mutation and (2) 2 truncating APTX muta-
tions. To test whether hypomorphic missense mutations are
clustered in a specific part of the histidine triad (HIT) do-
main,weperformed a second analysis inwhich patientswere
divided into the following 4 groups according to the type of
mutationand its location inAPTX: (1) homozygousp.Trp279*;
(2) two truncating mutations with at least 1 different from
p.Trp279*; (3) at least 1 missense mutation in the first part of
HIT domain, before the HITmotif (β sheets 2 and 3 and α he-
lix 2, containing the missense mutations p.Lys197Gln,
p.Ala198Val, Pro206Leu, andVal230Gly); and (4) at least 1mis-
sensemutation in the second part of the HIT domain at or af-
ter the part that includes theHITmotif (β sheets 4 and 5 andα
helix 3, containing the missense mutations p.Leu261Phe,
p.Asp267Gly, and p.Ser270Phe). The 2 groups and then the 4
groups were compared regarding their clinical, electrophysi-
ologic, imaging, and biochemical features. The second analy-
sis of the 4 groups was performed when all the mutations of
80 patients with AOA1 were known.
Statistical Analysis
Datawere analyzed fromJanuary 1, 2015, through January 31,
2016. All statistical analyses were performed with SAS soft-
ware for Windows (release 9.3; SAS Institute). The χ2 and the
Fisher exact tests were applied to reveal differences in pro-
portionsbetweengroupsorassociationsbetweencategoryvari-
ables.Weusednonparametric statistical tests for the analysis
of quantitative data because the variable distributionwas not
normal. We applied the Kruskall-Wallis test for comparisons
ofquantitativevariables across 3ormore independentgroups.
In case of statistically significant results, groups underwent
pairwise comparison, and thePvalueswereadjustedusing the
Bonferroni-Holm method. The linear associations between
quantitative variableswere assessed using the Spearman cor-
relation procedure. For all statistical tests, we considered
P < .05 as statistically significant.
Results
Eightypatients (46men[58%]and34women[42%];mean[SD]
age, 28.5 [13.7] years) from 51 families were diagnosed with
AOA1. Fifty-seven patients were new, and 23 had been de-
scribed previously.2,5,10
Clinical Data
Table 1 and Table 2 summarize the main features of the
patients with AOA1 (2 patients are shown in Video 1 and
Video 2). Patients originated from France (n = 23), Algeria
(n = 11), Morocco (n = 8), Tunisia (n = 4), Brazil (n = 3), Swit-
zerland (n = 3), India (n = 2), Belgium (n = 2), the United
States (n = 2), Ireland (n = 2), Israel (n = 2), Italy (n = 2),
Lebanon (n = 2), Rwanda (n = 2), Turkey (n = 2), the Nether-
lands (n = 1), Syria (n = 1), Portugal (n = 1), and North Africa
(without geographic precision) (n = 7). Oculomotor apraxia
correlated positively with the SARA score; the higher the
SARA score, the more frequent the OMA (z = 1.739; P = .04).
The progression rate of the disease (SDFS:DD ratio) corre-
lated positively with the presence of movement disorder;
the faster the disease progression, the more intense the
movement disorder (z = 1.839; P = .03).
Biological Data
Biological data regarding the biomarkers are presented in
Table 2. Longer DDwas correlatedwith lower albumin serum
levels (ρ = −0.532; P < .01); the longer the DD, the higher the
serumAFP level (ρ = 0.637; P < .01) and the higher the serum
total cholesterol level (ρ = 0.571;P < .01). Thebiomarkersmea-
sured with lower levels of albumin correlated with increased
total cholesterol (ρ = −0.451; P = .02) and AFP (ρ = −0.505;
P < .01) levels. We did not find any phenotype-genotype cor-
relation according to AFP level.
Mutation Analysis
We identified 8 newmutations (Table 3 and Figure 1). Seven of
thesemutationswere estimated to result in amajor disruption
ofaprataxinand included2nonsensemutations (p.Gln187*and
p.Tyr195*), 1 large in-frame deletion (del exon4), and 4 frame-
shift mutations (c.336_337delCA, c.774_775insCTTTCAACTA,
c.940_956del17, and c.596delG). Only 1 mutation was a mis-
sensemutation(p.Ser270Phe), resultinginnonconservativesub-
stitution affecting an amino acid residue conserved in all eu-
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karyotes and was predicted to be pathogenic by 2 different
algorithms (Sift score, 0.02; PolyPhen2 score, 1.00).
Thep.Trp279*mutation, initially only associatedwith the
Portuguese founder haplotype, was found in 53 of 80 pa-
tients (66%). Forty-one patients (51%) were homozygous for
p.Trp279*.
Genotype-Phenotype Correlation
Patients with AOA1were divided between thosewith at least 1
missensemutation inAPTX (n = 15)andthosewith2truncating
mutations(n = 65).Patientswithatleast1missensemutationhad
a higher mean (SD) age at onset (17.7 [11.4] vs 5.2 [2.6] years;
P < .001) anda less severemean (SD)SDFSscore (2.7 [1.5]vs4.4
[1.5];P < .01).Correlations foroculomotorapraxia (83%vs 17%;
P < .001),oculocephalicdissociation (82%vs18%;P = .02), and
headthrust(83%vs17%;P = .01)werefoundwiththesecondtype
ofmutation, which occurredmore frequently in patients with
deletion or truncatingmutations than in patients with at least
1 missensemutation.We found no difference between groups
regarding other qualitative or quantitative variables.
In the second analysis, the patients with AOA1 were di-
vided into the 4 groups described in the Genotype-Phenotype
Correlation Studies subsection of the Methods, including 41
(51%) in group 1, 24 (30%) in group2, 10 (13%) in group3, and5
(6%) in group4.Mean (SD) age at onsetwas higher for patients
in group 4 (25 [10.9] years) compared with group 3 (13.4 [10.1]
years;P = .03), group1 (5.8 [2.5]years;P < .01), andgroup2 (2.0
[2.5] years; P < .01).
Comparison of AFP LevelWith Control Groups
Levels of AFP in controls without ataxia, patients with AOA2,
patientswith SLOCA, andpatientswithAOA1 arepresented in
Figure 2. ThemedianAFP levelwas significantly higher in pa-
tientswithAOA1 (6.0ng/mL; range, 1.1-17.0ng/mL;mean [SD],
6.6 [4.0] ng/mL) compared with patients without ataxia (3.4
ng/mL; range, 0.8-17.2 ng/mL; mean [SD], 41. [2.8] ng/mL;
P < .01) and patients with SLOCA (3.5 ng/mL; range, 1.4-12.7
ng/mL;mean [SD], 4.1 [2.4] ng/mL; P < .01). Median AFPwas
significantlyhigher inpatientswithAOA2 (32.2ng/mL; range,
5.0-185.0ng/mL;mean[SD],42.1 [34.6]ng/mL)comparedwith
patientswithAOA1 (P < .01), controlswithout ataxia (P < .01),
andpatientswithSLOCA (P < .001). Thedifference inAFP lev-
els between the groups without ataxia and with SLOCA were
not significant (P > .99).
Discussion
Wehereindescribe theclinical, biomarker, andmolecular find-
ings of the largest international cohort, to our knowledge, of
patientswithAOA1 reported thus far. Themost frequent clini-
cal findings consistedof early-onset cerebellar ataxiawith cer-
Table 1. Main Qualitative Variables of PatientsWith AOA1
Qualitative Variable
No. (%) of Patients
With AOA1
(N = 80)
Consanguinity 48 (60)
Oculomotor apraxia 49 (61)
Hypometric saccades 59 (74)
Nystagmus 49 (61)
Saccadic pursuit 57 (71)
Horizontal strabismus 20 (25)
Oculocephalic dissociation 40 (50)
Head thrust 36 (45)
Pes cavus 30 (38)
Scoliosis 27 (34)
Pyramidal signs 9 (11)
Intellectual disability 42 (53)
Current chorea 32 (40)
Chorea disappearing during the course of the
disease
6 (8)
Dystonia 20 (25)
Parkinsonism 2 (3)
Tremor 52 (65)
Myoclonus 8 (10)
Peripheral neuropathy 75 (94)
Cerebellar atrophy 79 (99)
Elevated AFP level (<7 ng/mL) 33 (41)
Decreased albumin level (3.5-4.8 g/dL) 50 (63)
Elevated total cholesterol level (0.5 -2 g/L) 45 (56)
Elevated LDL cholesterol level (<1.60 g/L) 34 (43)
Elevated CK level (10-200 U/L) 23 (29)
Abbreviations: AFP, α-fetoprotein; AOA1, ataxia with oculomotor apraxia type 1;
CK, creatine kinase; LDL, low-density lipoprotein.
SI conversion factors: To convert AFP tomicrograms per liter, multiply by 1.0;
total and LDL cholesterol to millimoles per liter, multiply by 0.259; and CK to
microkatals per liter, multiply by 0.0167.
Table 2. Main Quantitative Variables of PatientsWith AOA1
Quantitative Variables (n = 80) Median (Range) Mean (SD)
Age at onset, y 6 (2-40) 7.7 (7.4)
Age at examination, y 26 (9-59) 28.5 (13.7)
Duration of disease, y 17 (4-52) 20.9 (12.6)
Age at wheelchair use (n = 40), y 18 (4-57) 20 (11.4)
Duration of disease until wheelchair
use (n = 40), y
11.8 (2-38) 13.6 (8.6)
SARA score at last examinationa 28 (6-37) 26.4 (7.6)
SDFS score at last examinationb 6 (3-7) 5.5 (0.9)
Progression rate, SDFS:DD ratio 0.3 (0.1-1.2) 0.3 (0.2)
AFP level, ng/mL 6.0 (1.1-17.0) 6.6 (4)
Albumin level, g/dL 3.25 (1.78-4.59) 3.32 (0.65)
Total cholesterol level, g/L 2.1 (1.0-3.8) 2.2 (0.7)
LDL cholesterol level, g/L 1.7 (0.8-3.2) 1.7 (0.6)
CK level, U/L 185 (32-360) 168.4 (101.5)
Abbreviations: AFP, α-fetoprotein; AOA1, ataxia with oculomotor apraxia type 1;
CK, creatine kinase; DD, disease duration; LDL, low-density lipoprotein;
SARA, scale for the assessment and rating of ataxia; SDFS, spinocerebellar
degeneration functional score.
SI conversion factors: To convert AFP tomicrograms per liter, multiply by 1.0;
albumin to grams per liter, multiply by 10.0; total and LDL cholesterol to
millimoles per liter, multiply by 0.259; and CK tomicrokatals per liter, multiply
by 0.0167.
a Score range from0 to 40, with higher scores indicating moremore severe
ataxia.
b Scores range from 1 to 7, with higher scores indicating severe impairment.
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ebellar atrophy, axonal sensory-motor neuropathy, and even-
tual OMA (61% of cases). Overall, clinical, electrophysiologic,
and imaging features were in accordancewith those of previ-
ously reported smaller series.5,8,11 Amyotrophy,which should
also be included in the evaluation, can belong to the phe-
noype of AOA1.
The nonsensemutation p.Trp279*, first reported in asso-
ciationwith thePortuguese founderhaplotype,2was themost
frequent mutation, representing 66% of all mutated alleles.
This mutation was found in patients from several countries,
including the Netherlands, Belgium, Ireland, Morocco, Alge-
ria, and Israel, indicating an ancient origin. This finding sug-
gests thatmutationp.Trp279*maybe themost frequentAPTX
mutation in the white population.
Wefoundthat themeanageatonsetwashigher forpatients
withat least1missensemutationandthereforemanifestingaless
severepresentation.Oculomotor apraxia, oculocephalicdisso-
ciation,andheadthrustweremorefrequent inpatientswithde-
letionortruncatingmutationsthaninpatientswithat least1mis-
sensemutation.These results are consistentwith a recessively
inheriteddiseaseduetothe lossofproteinfunction,evenif such
findingswerenotobserved ina largecohortofpatientsaffected
withAOA2duetosenataxinlossoffunction.16 Inourstudy,OMA,
althoughnot auniversal finding,was correlatedwith theSARA
score, suggesting that OMA is amarker of an advanced formof
AOA1.Oculomotorapraxiaisalsovariablypresentinpatientswith
AOA2andataxia-telangiectasia.TheabsenceofOMA,however,
was frequently observed in a significant number of patients,
which reinforces the notion that the diagnosis of AOA1 should
still beconsidered inpatientswithautosomal recessivecerebel-
lar ataxias lackingOMA.
Some missense mutations (p.Lys197Gln, p.Ala198Val,
p.Pro206Leu, and p.Val230Gly) appeared to be associated
with a severe phenotype, whereas others (p.Leu261Phe,
Figure 1. Position of theMutationsWith Respect to the Aprataxin (APTX) Protein Domains
Missense mutations :
Deletion, insertion, splice, or
nonsense mutations: 
Domains: FHA-like ZincfingerHIT
Val230Gly
Lys197Gln
Ala198Val
Pro206Leu
Asp267Gly
Ser270Phe
Leu261Phe
Gln187*
Arg199Leufs*15
Ala292Glufs*2  
Glu162_Gln181del20
Trp279*
Arg306*  
Lys314Serfs*2
Tyr195*
Val259Leufs*14
Val182Profs*12
His112Glnfs*10
   
The histidine triad (HIT) motif (HxHxH) is highlighted in green. The deletion,
insertion, and splice site mutations are translated into estimated protein
consequences. Correspondence for novel mutations (red) is indicated in
Table 3; c.544-2A>G (acceptor) and c.770 + 1G>A (donor) exon 5 splice site
mutations are estimated to result in frameshift exon 5 skipping
p.Val182Profs*12; c.875-1G>A (last) exon 7 acceptor splice site mutation is
estimated to result in use of a minor alternative exon 7’ (isoform coded by
transcript NM_175069) Ala292Glufs*2. The position of the in-frame exon 4
deletion (Glu162_Gln181del20) is indicated by a double arrow that represents
the extent of internal peptide deletion. The large deletion of exons 1 to 4 is not
represented because it is estimated to result in complete absence of APTX
transcription.
Table 3. Description of the 8 NewMutations
Patient No.
(Geographic Origin) Nucleotide Change (Exon) Amino Acid Change Mutation Status
8 (Tunisia) c.809C>T (exon 6) p.Ser270Phe Compound heterozygous
(c.875-1G>A (exon 7))
19 (France) c.336_337delCA (exon 3) p.His112Glnfsa10 Compound heterozygous
(c.617C>T (exon 5)
p.Pro206Leu)
30 (France) c.774_775insCTTTCAACTA
(exon 6)
p.Val259Leufsa14 Compound heterozygous
(c.837G>A (exon 6)
p.Trp279a)
32 (Turkey) c.940_956del17 (exon 7) p.Lys314Serfsa2 Homozygous
41 and 42 (Brazil) del exon 4 p.Glu162_Gln181del20 Homozygous
45
(the Netherlands)
c.559C>T (exon 5) p.Gln187a Compound heterozygous
(c.837G>A (exon 6)
p.Trp279a)
46 and 47
(Morocco)
c.585C>A (exon 5) p.Tyr195a Homozygous
48, 49, and
50 (India)
c.596delG (exon 5) p.Arg199Leufsa15 Homozygous
Abbreviations: del, deletion;
ins, insertion; fs, frameshift.
a Indicates stop codon.
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p.Asp267Gly, and p.Ser270Phe) seemed to be linked with a
milder presentation. Aprataxin includes the following 3 do-
mains: (1) the PANT domain (PNKP-AOA1 N-terminal do-
main), also designated as putative forkhead-associated (FHA)
domain, corresponding to the N-terminal region of ap-
rataxin; (2) a HIT domain; and (3) a C-terminal domain con-
taining adivergent zinc-fingermotif.2 Aprataxin is involved in
DNAsingle-strandbreak repair, interactionswith several pro-
teins involved in the base excision repair and ribonucleotide
excision repair pathways, andactions inRNA-DNAdamage re-
sponse to protect the genome from the accumulation of ad-
enylyl ribosylated 5′ termini.17 Of note, the milder missense
mutations are located within or just downstream of the HIT
motif HVHLH of the HIT domain, whereas the other mis-
sense mutations are located in the first part of the HIT do-
main. The HITmotif is the catalytic site for adenosinemono-
phosphate removal activity from the 5′ terminus of aborted
ligationproducts.18,19Missensemutations localized in theHIT
domain lead to APTX destabilization with a severe quantita-
tive reduction and alteration of the subcellular distribution,
being perinuclear (cytoplasmic) instead of nuclear and
nucleolar.20Somegenotype-phenotypecorrelationshavebeen
previously reported in patientswithAOA1. In 15 patientswith
AOA1,Date et al3 reported that patients carryingp.Pro206Leu
and p.Val263Glymutations appear to have a later onset and a
milder phenotype than do those carrying c.689_690insT or
c.del840delT frameshift mutations. In a series of 28 patients
with AOA1, Criscuolo et al21 found that patients carrying
p.His201Gln, p.Pro206Leu, and p.Leu223Pro presented with
a later age at onset, ranging from 28 to 40 years. In 2011,
Yokoseki et al9 described 58 patients with AOA1 and demon-
strated that those homozygous for c.689-690insT (40 pa-
tients) had a more severe phenotype than did those with a
p.Pro206Leuorp.Val263Glymutation (9patients). Inourstudy,
themilder presentation associatedwith thep.Pro206Leumu-
tation did not reach significance, presumably because the as-
sociationwith severity is small andour study included fewpa-
tients with p.Pro206Leu. However, we present, to our
knowledge for the first time,probablybecauseof the large size
of the sample, a genotype-phenotype correlation for themis-
senseAPTXmutationsaccording toposition relative to theHIT
domain.
Results regardingpotential biomarkers inAOA1were inter-
esting. The serumAFP levelwas elevated in 32patients (40%).
Previous studies22 have only reported 3 cases of AOA1 with
slightly increased AFP levels (7.8, 14, and 14.5 ng/mL). For the
first time, toourknowledge,wereveal that theserumAFP level
could be a biomarker of AOA1 that increases with DD. Our re-
sults further suggest that a slightly increasedAFP level in a pa-
tient with early-onset ataxia is potentially compatible with
AOA1.22Hypoalbuminemiawasfoundin62%ofpatients,which
is comparable with findings in other series.9,22 Our biological
data confirm that serum albumin levels decrease and choles-
terol levels increase during the course of the disease.5,8 Hypo-
albuminemia and hypercholesterolemia are the most charac-
teristicbiochemical findings inAOA1,whereasanelevatedAFP
level is typicalofpatientswithataxia-telangiectasiaorAOA2and
maybeencountered inAOA423andtosomeextent inARCA3.1,15
Modifications of albumin and serumAFP levelswere iden-
tified inpatientswithAOA1 inour study, althoughnoalteration
ofAFPserumlevelwasdetectedduringtheclinicalcourseof the
disease in a large series of 90patientswithAOA2.16 Even if AFP
isabiomarkerofrecessiveataxiaswithperipheralneuropathyand
optional OMA (such as AOA1, AOA2, ataxia-telangiectasia, and
AOA4), theunderlyingbiological linkbetweenAFPlevelandcer-
ebellarataxia,peripheralneuropathy,andoculomotorabnormali-
ties is still unknown. In contrast to ataxia-telangiectasia, to our
knowledge, sensitivity to ionizingradiation24andsusceptibility
to cancer are not increased in AOA1 and AOA2.25 Patients with
AOA1presentedwithnormalprotein intakeandrateofalbumin
degradation; decreased synthesis of albumin in the liver is sus-
pectedtobethecauseofhypoalbuminemia.26ElevatedAFPlev-
els andhypoalbuminemiaare foundoneither sideof transcrip-
tional impairment in the liver. Inhepatocytes,AFPandalbumin
geneshaveoppositetranscriptionalregulatorymechanisms.27El-
evatedAFPlevelsinataxia-telangiectasiaandAOA2likelyalsopro-
ceedfromliver transcriptionaldysregulation.1 In thecurrentera
ofsearchingforbiomarkers, theimportanceofAFPmustbehigh-
lighted,especiallybecauseitsserumlevel increasesprogressively
during the course ofAOA1 in the sameway that serumalbumin
levelsdecreaseprogressively. Ifourdataareconfirmedbyfurther
studies, this increase could be of interest for designing further
clinical trials devoted toARCAwith elevatedAFP levels.
Movement disorders reported in our series included cho-
rea, dystonia, tremor, and, less frequently, myoclonus. Pro-
portions ofmovement disorderswere similar to the40%cho-
rea, 16%dystonia, and8%myoclonus in the studybyYokoseki
et al9 (32 patients [40%], 20 patients [25%], and 8 patients
[10%], respectively, in our study). Chorea is classically de-
scribed in AOA1.5,9,22,28 Mild to severe dystonia5,9,29 and in-
tentional tremor28,30 have already been described in some
cases. We found that movement disorders are more frequent
in patients with rapid disease progression.31,32
Figure 2. Levels of α-Fetoprotein (AFP)
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Distribution of AFP levels in 102 control individuals (no ataxia), 76 patients with
sporadic late-onset cerebellar ataxia (SLOCA), 74 patients with ataxia with
oculomotor apraxia type 2 (AOA2) described previously,16 and 80 patients with
AOA1 in our study. The density of points is presented as log10 of the AFP serum
level.
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Limitations
The primary limitation of this study is the retrospective na-
ture. Subsequently, repeated measures of biomarkers to bet-
ter see their progression are lacking.
Conclusions
Our studydescribes, toourknowledge, the largest seriesofpa-
tientswith AOA1 and strengthens the delineation of the clini-
cal,molecular, andbiomarker characteristics of this rare form
of ARCA. We demonstrate that OMA may be lacking, despite
themisleading name of AOA1; AFP serum level may be a new
biomarker of AOA1; the p.Trp279* mutationmay be themost
frequent APTX mutation in the white population; and mis-
sense APTXmutations may be associated with a milder phe-
notype. Given the limitations of a retrospective study, an ad-
ditional prospective study with repeated measures of
biomarkers (albumin, cholesterol, andAFP levels) is required
to strengthen our findings.
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